Abstract:Expression of membrane-bound Fas ligand (FasL) by colorectal cancer cells may allow the development of an immune-privileged site by eliminating incoming tumour-infiltrating lymphocytes (TILs) in a Fas-mediated counter-attack. Sporadic colorectal cancer can be subdivided into three groups based on the level of DNA microsatellite instability (MSI). High-level MSI (MSI-High) is characterized by the presence of TILs and a favourable prognosis, while microsatellite-stable (MSS) cancers are TIL-deficient and low-level MSI (MSI-Low) is associated with an intermediate TIL density. The purpose of this study was to establish the relationship between MSI status and FasL expression in primary colorectal adenocarcinoma. Using immunohistochemistry and a selected series of 101 cancers previously classified as 31 MSI-High, 30 MSI-Low, and 40 MSS, the present study sought to confirm the hypothesis that increased TIL density in MSI-High cancers is associated with low or absent membrane-bound FasL expression, while increased FasL in MSS cancers allows the killing of host TILs. TUNEL/CD3 double staining was also used to determine whether MSS cancers contain higher numbers of apoptotic TILs in vivo than MSI-High or MSI-Low cancers. Contrary to the initial hypothesis, it was found that MSI-High cancers were associated with higher FasL expression (p = 0.04) and a stronger intensity of FasL staining (p = 0.007). In addition, mucinous carcinomas were independently characterized by increased FasL expression (p = 0.03) and staining intensity (p = 0.0005). Higher FasL expression and staining intensity did not correlate with reduced TIL density or increased numbers of apoptotic TILs. However, consistent with the hypothesis that curtailment of the host anti-tumour immune response contributes to the poor prognosis in MSS cancers, it was found that apoptotic TILs were most abundant in MSS carcinomas and metastatic Dukes' stage C or D tumours (p = 0.004; p = 0.046 respectively). This study therefore suggests that MSS colorectal cancers are killing incoming TILs in an effective tumour counter-attack, but apparently not via membrane-bound FasL.

Abnormal Expression of Metallothionein and FasL in Rectal Carcinoma Tissues

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

[The influence of FasL gene expression upon hepatic metastasis of colorectal carcinoma]

Metallothionein Expression in Hepatocellular Carcinoma.

Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma

Clinical Significance of Fas and FasL Protein Expression in Gastric Carcinoma and Local Lymph Node Tissues

Significance of Fas and FasL Protein Expression in Cardiac Carcinoma and Local Lymph Node Tissues.

[Expression of Fas Ligand on Peritumoral Lymphocytes and Its Association with Apoptosis of Colorectal Carcinomas].

Expression and Prognostic Significance of Metallothionein in Non-small Cell Lung Cancer

Expression of matrix metalloproteinase-7 and Fas and their significances in gastric carcinoma

EXPRESSIONS OF c-Met AND Fas PROTEINS IN GASTRIC CARCINOMA AND THEIR RELATIONSHIP

Fas Ligand Expression in Colon Cancer: A Possible Mechanism of Tumor Immune Privilege

Metallothioneins may be a potential prognostic biomarker for tumors: A Prisma-compliant meta-analysis.

Expression of membrane type-Ⅰmatrix metalloproteinase-mRNA in human laryngeal squamous cell carcinoma

Expression and correlation of HIF-1α and MMP-7 in rectal carcinoma

Vascular endothelial growth factor C correlated with lymphatic metastasis in middle-low rectal carcinoma

Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status

FasL Expression in Human Colon Carcinomas

The Expression and Clinical Significance of Fas and FasL in Human Breast Carcinoma

Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival

[The role of Fas/Fas ligand in tumorgenesis, immune escape, and counterattack in colonic cancer].